Life Biosciences has shared new updates from its glaucoma study for its cellular reprogramming drug, according to STAT. The company is developing the therapy as a potential treatment for glaucoma, a leading cause of blindness. The update offers a fresh look at a once-controversial scientific strategy that aims to rejuvenate or restore the function of damaged cells rather than simply slow their loss.
The news arrives as the broader U.S. biotech sector faces headwinds. STAT notes that NIH funding uncertainty is thwarting researchers across the country, and other companies are also stumbling — Argenx recently saw a late-stage study failure for an autoimmune disease drug. The glaucoma update from Life Biosciences is therefore one bright spot in a week of mixed biotech news, though the full details of the data remain behind STAT's paywall.